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Human Muscle-Derived Cell Populations Isolated
by Differential Adhesion Rates: Phenotype and Contribution
to Skeletal Muscle Regeneration in Mdx/SCID Mice
Steven M. Chirieleison, B.S.,1,2 Joseph M. Feduska, B.S.,1 Rebecca C. Schugar, B.A.,1,3
Yuko Askew, M.D., Ph.D.,1 and Bridget M. Deasy, Ph.D.1,4,5
Muscle-derived stem cells (MDSCs) isolated from murine skeletal tissue by the preplate method have displayed
the capability to commit to the myogenic lineage and regenerate more efficiently than myoblasts in skeletal and
cardiac muscle in murine Duchenne Muscular Dystrophy mice (mdx). However, until now, these studies have
not been translated to human muscle cells. Here, we describe the isolation, by a preplate technique, of candidate
human MDSCs, which exhibit myogenic and regenerative characteristics similar to their murine counterparts.
Using the preplate isolation method, we compared cells that adhere faster to the flasks, preplate 2 (PP2), and cells
that adhere slower, preplate 6 (PP6). The human PP6 cells express several markers of mesenchymal stem cells
and are distinct from human PP2 (a myoblast-like population) based on their expression of CD146 and myogenic
markers desmin and CD56. After transplantation to the gastrocnemius muscle of mdx/SCID mice, we observe
significantly higher levels of PP6 cells participating in muscle regeneration as compared with the transplantation
of PP2 cells. This study supports some previous findings related to mouse preplate cells, and also identifies some
differences between mouse and human muscle preplate cells.
Introduction
Duchenne muscular dystrophy (DMD) is a muscledisease characterized by extensive and progressive
muscle degeneration due to the lack of dystrophin protein
expression at the sarcolemma of muscle fibers.1 The lack of
dystrophin at the membrane disrupts the structural connec-
tion between the cytoskeleton and the extracellular matrix,
thus resulting in muscle fiber necrosis and weakness.2,3
Onset of symptoms occurs early in childhood (between 2
and 6 years of age), and in recent years, survival has been
improved to early adulthood by using approaches such as
mechanical ventilation.4,5 Effective treatment of DMD will
likely require long-term replacement of the missing dystro-
phin protein. Muscle stem cells, such as satellite cells, are
the resident postnatal, progenitor repair cells for skeletal
muscle.6–8 Due to the natural tendency of muscle progenitor
cells to fuse with existing or newly forming muscle fibers,
cell transplantation approaches to treating DMD are prom-
ising. Indeed, 20 years ago, Partridge et al. first showed that
transplantation of normal myoblasts can restore dystrophin
expression in dystrophin-deficient muscle of mdx host mice,9
and this spurred enthusiasm for human clinical trials based
on this approach.8,10–13 However, some studies exhibited
limited success, and this was associated with host immune
rejection, poor donor cell survival, proliferation and migra-
tion, and challenges in systemic delivery.
Although the transplantation of normal myoblasts re-
stores dystrophin expression in some myofibers in mdx
mice9,14–16 and patients with DMD,10,17,18 the use of less-
committed muscle stem cells may improve the efficacy of
this approach. Reports now describe the heterogeneity of
muscle stem cells; in particular, a subset of satellite cells
may be capable of repopulating the satellite pool,6,19 or
different progenitors may derive from interstitium or en-
dothelial sources, for example7; and transplantation of
these cells may lead to better muscle regeneration. A pop-
ulation of mouse muscle-derived stem cells (msMDSCs)
with an undefined relationship to satellite cells has been
described20,21; msMDSCs have stem cell characteristics
that may help overcome hurdles associated with myoblast
transplantation therapy. In particular, msMDSCs, isolated
by a preplate method, exhibited an increased capacity for
muscle regeneration in the mdx mice as compared with
myoblasts.21 The preplate-isolated msMDSCs also demon-
strate long-term self-renewal and multi-lineage differentiation
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capability.21–23 Extensive examination of msMDSCs have
been performed to better understand how the isolation
procedures selects for this population as well as how these
cells are distinct from myoblasts and what may be their
origins.21,24–30 However, less work has been performed to
determine whether this work can be translated to human
cells and whether these cells can be isolated from human
tissue by using the same method.
We and others have examined the regenerative efficiency
of various human muscle stem cells isolated by fluorescence
activated cell sorting (FACS) purification for skeletal muscle
repair; however, no studies to date report on the human
preplate-derived cells that would be a counterpart to the
well-described msMDSC.31 Recent work has focused on the
isolation of progenitor cells associated with the human
blood vessels, including CD34+CD144+CD56+ myogenic-
endothelial cells,32 CD146+ pericytes,7 mesoangioblasts,33 and
CD133+ progenitor cells,34 the latter of which was investigated
in a recent phase I clinical trial.35 In contrast to those discussed
so far, the human skeletal MDSCs (hMDSCs) isolated by the
preplate technique have yet to be examined for their in vivo
myogenic repair capacity. Human muscle-derived cells have
been isolated by the preplate technique from muscle tissue for
several years;36–38 however, examination of these cells in skel-
etal muscle regeneration models has not been performed.31
Here, we investigate human muscle-derived cells obtained
by the preplate technique in transplantation studies using the
mdx/SCID mice. We examine phenotypic differences and the
regenerative potential of two specific populations of human
muscle-derived cells isolated by differential adhesion rates dur-
ing the preplate method—preplate 2 (PP2) cells which are faster
to adhere, and preplate 6 (PP6) cells that are slower in adhering.
Materials and Methods
Cell isolation
Human muscle-derived cells were isolated by way of
differential adhesion rates by using a modification of meth-
ods as previously described.21,39 Human skeletal muscle was
enzymatically digested by using collagenase, and dispase
and serial preplating was performed to separate cell fractions
preplate 1 (PP1), PP2, and preplate 3 (PP3) through to PP6.
Cells that adhere to noncollegenated tissue culture plastic
flasks within the first 30min were PP1 cells. Medium and
nonadhered cells from the PP1 flasks were then transferred
to a fresh flask, and cells that adhered during 30 to 60min
were termed ‘‘PP2’’ flasks. Again, media and nonadhered
cells were transferred to fresh flasks and allowed to adhere
such that PP3 cells were those that adhered 1 to 2 h post-
plating. PP4 cells adhered after 2 to 24 h, and PP5 cells ad-
hered between 24 and 48h. PP6 cells adhered between 48
and 120 h. During the isolation process, cells were grown in
Dulbecco’s modified Eagle medium (Gibco) with 20% fetal
bovine serum and 0.5% Chick Embryo Extract. Cells were
then frozen for later use. For the current study, we compared
the fast adhering cells from PP2 and slow adhering cells from
PP6, which would be most comparable to msMDSCs.21
Cell culture
Candidate populations were grown in EGM-2 media
(Lonza) at a density of 600–800 cells/cm2 under standard
conditions (5.0% CO2, 37C). Cells were passaged every
72–96 h by treatment with 0.05% trypsin (Invitrogen) diluted
1:1 in 1· Dubecco’s phosphate buffer solution (DPBS;
Invitrogen) at 37C for 3–4min. Detached cells were then
washed in 1 · DPBS, centrifuged, and suspended in 1.0mL
of media for counting via hemocytometer.
Flow cytometry analysis
PP6 and PP2 cells were analyzed for expression of cell
surface cluster of differentiation markers CD34, CD73,
CD90, CD146 (BD Pharmingen), CD44, CD105 (Invitrogen),
CD56 (BioLegend), CD45, and CD144 (eBioscience) at the
first three passages in culture. Cells were initially incubated
in a blocking solution of 10% goat serum in DPBS (Vector)
for 30min on ice before primary antibody treatment. After
primary antibody treatment, and secondary labeling with
streptavidin-Allophycocyanin (BD Pharmingen) where ap-
propriate, cells were washed, suspended in 300 mL of 1 ·
PBS (Invitrogen), and fixed with 80 mL of 5% formalin. Flow
cytometric acquisition and analysis was performed by using
an FACSCalibur (Becton Dickinson), and expression was
determined as fluorescence emission levels exceeding 98%
of unlabelled controls.
Immunocytochemistry
PP6 and PP2 cells were plated in a 24-well plate at a density
of 600–800 cells/cm2. After 72–96h, cells were fixed with 100%
cold methanol (Fisher), blocked in 10% horse serum in DPBS,
labeled with either primary 1:250 mouse anti-desmin (Sigma)
or mouse anti-Myosin Heavy Chain Fast (Sigma) antibody,
followed by secondary labeling with 1:250 biotinylated goat
anti-mouse IgG (Vector Laboratories), 1:500 streptavidin-
Cy3 (Sigma); nuclei were counterstained with 300 nM 4¢-6-
diamidino-2-phenylindole (DAPI) (Invitrogen). After staining,
images of cells were taken on a Nikon TE-2000-U microscope
(Nikon Instruments) with Spot RT-ke camera and software
(Diagnostic Instruments) and then quantified as desmin posi-
tive nuclei per total nuclei. Positive expressionwas determined
by setting exposure using unlabelled controls.
Bioinformatic live cell imaging
Although traditionally established tools such as flow
cytometry and molecular methods are frequently used to
characterize cells, the use of time-lapsed microscopy to re-
veal additional cell behaviors represents a novel method to
characterize potentially therapeutic cells. In this study, we
used a previously described method to measure a number
of cell features from time-lapsed images.40–42
Cells seeded at 600–800 cells/cm2 in a 24-well plate were
incubated in a cell culture system with dynamic imaging.40
Images were captured at 10-min intervals over 72–96 h. To
measure mean cell area, we imported time-lapsed image
sets to ImageJ (NIH), and at 5 different time points, 10
separate cells were traced over three consecutive frames,
thus yielding 30 measurements per time point. Averaging
mean cell area across time points yielded values for the
population. Cell velocity was determined by tracking the
location of cell centroid in three consecutive images, di-
viding distance change of centroid across consecutive
frames by the time interval of 10min between scans yielded
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single cell velocity. Averaging 10 separate cell measure-
ments at each time point and averaging time point values
yielded cell velocity for each population. A similar method
was used to find mean circularity.
In vivo regeneration
For PP2 (n= 3 PP2 populations with a total of 18 muscles)
and PP6 (n= 3 PP6 populations with a total of 26 muscles),
100,000 cells in 30mL PBS were transplanted to the gastroc-
nemius muscles of 8- to 10 week-old mdx/SCID mice. For
control muscles, we also used (1) sham injections of 30mL PBS
(n= 4) and (2) no transplantation or no injection mdx/SCID
muscles (n = 5). Muscles were harvested 2 weeks post-
transplantation and frozen sectioned into 10-mm sections.
Some serial sections were stained with hematoxylin and
eosin; others were stained with specific antibodies. For
immunohistochemical analysis, sections were blocked in
10% donkey serum in DPBS ( Jackson ImmunoResearch),
incubated in primary 1:200 rabbit polyclonal anti-mouse/
anti-human dystrophin (Abcam, Cat #15277), followed by
1:250 Alexa Fluor 594 donkey anti-rabbit IgG (Invitrogen),
and nuclei were counterstained with 300 nM DAPI (In-
vitrogen). Sections were then counted by visual inspection
on a Nikon E800 (Nikon Instruments) with a 20 · objective
for dystrophin positive fibers, and the greatest number of
dystrophin positive fibers in a single muscle cross-section
yielded the Regeneration Index, or number of dystrophin-
positive fibers, for that muscle. For sham PBS-injected
muscles and no-injection muscles, we quantified the num-
ber of revertant dystrophin positive fibers in the gastroc-
nemius cross-section. The regeneration index (RI) of cell
transplantations and the number of revertant fibers in
control muscles are plotted on the same graph in Figure 5
for ease of comparison. Centro-nucleation was quantified as
the percentage of myofibers in a given section that show
nuclei within the fiber center and clearly not peripheral.
Fiber diameter and area were measured by using ImageJ
(NIH) line and trace tools.
For detection of human dystrophin, slides were stained
using the Vector M.O.M. Immunodetection Kit (Vector La-
boratories) with 1:10 mouse anti-human dystrophin (DYS3;
Novocastra) primary antibody, 1:250 biotinylated goat anti-
mouse IgG secondary antibody (Vector Laboratories), and
1:500 streptavidin-Cy3 (Sigma); nuclei were counterstained
with 300nM DAPI (Invitrogen). Nuclei sex was confirmed by
fluorescence in situ hybridization. Degenerate oligonucleotide-
primed PCR-labeled Y probes were used to label the Y-specific
nuclear antigen in nuclei of the male host mouse to visualize
fusion with recipient fibers.
Results and Discussion
Two human muscle-derived cell populations, separated at
the time of isolation by their rates of adhesion, were obtained
by a modified preplate technique.21,39 The 2 populations
were termed ‘‘PP2’’ (adhering within first hour) and ‘‘PP6’’
(adhering after 2–5 days), corresponding to their initial rate
of adherence during the isolation procedure (Fig. 1). Pre-
viously, mouse myoblasts (fast adhering) could be separated
from MDSCs (slowly adhering) based on adherence rates.21
We examined whether the human muscle-derived PP2
and PP6 populations might be further distinguished by
molecular surface marker phenotype and expression of the
myogenic-related intermediate filament desmin. We per-
formed flow cytometry for endothelial and blood-cell-related
surface markers CD34, CD45, CD144, and CD146; mesen-
chymal stem cell-related surface markers CD44, CD73, CD90,
and CD105; and the myogenic-related surface marker CD56
for the PP2 and PP6 populations. Both PP2 and PP6 popu-
lations were negative ( < 2%) for CD34, CD45, and CD144
and consistently, highly positive for mesenchymal markers
( > 95%) CD44, CD73, CD90, and CD105, thus exhibiting little
variability between samples or across PP2 and PP6 popula-
tions (Fig. 2A). Slow adhering cells showed lower CD146
levels (Fig. 2B) and lower CD56 levels (Fig. 2B) as compared
with PP2 cells (CD146: 31% vs. 64%, and CD56: 46% vs. 79%,
respectively, PP2 populations not shown in Fig. 2). There is
a significant positive correlation between the level of ex-
pression of CD146 and the myogenic marker CD56 in both
PP6 and PP2 populations ( p< 0.05, Fig. 2C). We also observe
lower levels of myogenic marker desmin by immu-
nocytochemisty (in PP6 populations as compared with PP2
populations; 34% vs. 77%, Fig. 2D). In sum, PP2 and PP6
populations exhibited significant differences in the percent-
age of cells expressing CD146, CD56, and desmin (Fig. 2E,
p < 0.005). Examination of mesenchymal markers was not
previously performed for preplate-derived MDSC isolated
from other species;43–50 however, a study of CD56-sorted
cells showed MSC markers CD90 and CD106 positivity on
MDSCs from craniofacial muscles.51 Our findings related to
desmin and CD56 are consistent with murine myoblast and
MDSC studies.21,22,48,52
Interestingly, the human PP2 and PP6 cells exhibited a few
differences in proliferative characteristics related to their
population doubling time (PDT), cell division time (DT), or
mitotic fraction (Fig. 3A–C). The mean PDT for PP6 cells was
34 h, whereas the PDT for PP2 cells was 31 h (not signifi-
cantly different, Fig. 3A). There was no significant difference
in the cell cycle time, or DT, between PP6 and PP2 cells.
These results are in contrast to the similar mouse muscle cell
populations that showed faster DT in myoblasts as com-
pared with msMDSCs21; however, it should be noted that
myoblasts readily differentiate and fuse such that they have
limited long-term expandability.21 In addition, similar to the
mouse populations, both human PP2 and PP6 populations
exhibited morphological heterogeneity (Fig. 1); however, on
average, the human PP6 cells displayed larger area or cell
spreading in monolayer as compared with PP2 cells (Fig.
3D). Finally, we also examined the migration rates (although
it has not been shown, in vitro migration capacity may relate
to cell dispersion post transplantation) of the human muscle
populations. We found that PP2 cells exhibited lower cell
velocity as compared with PP6 cells (0.41vs. 0.66 mm/min);
this had not been previously examined in mouse popula-
tions. A summary of comparisons between human and
mouse PP2 and PP6 cells is provided in Supplementary Table
T1; Supplementary Data are available online at www
.liebertonline.com/tea.
We next examined myogenic activity of the PP2 and PP6
populations. Reverse Transcription polymerase chain reac-
tion (RT-PCR) results showed the populations’ expression
of several myogenic markers—myf-5, myoD, and myogenin
(Fig. 4A). RT-PCR analysis (Fig. 4A) also confirmed the
expression of desmin and myosin as detected by
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immunochemistry; however, we did not detect clear signif-
icant differences in these markers by RT-PCR. In both PP2
and PP6 groups, there were populations that expressed the
more differentiated markers myogenin and myosin, whereas
some populations in these groups did not express these
markers. Previously, others reported that mouse slowly ad-
hering MDSCs expressed myoD,43,45 and this was similar to
the levels expressed by myoblasts.21 Our findings, showing
that a smaller percentage of human PP6 is desmin positive
(34%), are consistent with a similar report by some of us in
which msMDSC populations were *15% desmin positive,
and the mouse PP2 myoblast-like populations were > 80%
desmin positive.21 However, several other reports show that
desmin expression is high in MDSC populations.25,43,45,51
Both PP2 and PP6 muscle cell populations exhibited the
capacity to differentiate to the myogenic lineage as demon-
strated by fast myosin heavy chain and multi-nucleate
myotubes in vitro (Fig. 4B).
Since the most striking difference between mouse myo-
blasts and MDSCs was their in vivo regeneration capacity, we
performed cell transplantations of the human PP2 and PP6
populations to gastrocnemius muscles of mdx/SCID mice.
Two weeks after transplantation of 100,000 cells, we per-
formed immunostaining for dystrophin in the cross-sections
of muscle tissue. We quantified the RI as the mean num-
ber of dystrophin positive fibers per 105 donor cells. We
detected centro-nucleated muscle fibers in both PP2 and
PP6-transplanted muscles (Fig. 5A, B, respectively), which
corresponded with regions of dystrophin positive fibers
(Fig. 5C, D). The mean RI after transplantation of PP6 (71 – 4)
was significantly higher than the mean RI after transplanta-
tion of PP2 (58– 5, p= 0.046). Both PP2 and PP6 transplan-
tations resulted in more dystrophin-positive fibers than
nontransplanted muscles ( p = 0.024 and 0.001, respectively)
or sham transplanted muscles (32– 4, standard error,
p= 0.023 and 0.001) (Fig. 5E).
Human donor cells from both preplate fractions appear to
contribute to dystrophin-positive myofibers primarily
through fusion with host fibers. The mean fiber diameters
were not significantly different compared with the dystro-
phin-negative fibers in the nontransplanted/no injection
muscles (PP2: 34– 6mm, PP6: 40– 8mm, and Host: 39 – 15mm,
Fig. 6A). Similarly, the mean fiber cross-sectional areas
of dystrophin positive fibers resulting from PP2 or PP6
transplantations were not significantly different from host
fibers in nontransplanted muscle (PP2: 1030– 420 mm, PP6:
1430– 650 mm, and Host: 1130– 660 mm, Fig. 6B). In rare in-
stances, we observe small dystrophin positive fibers that
could indicate de novomyofiber formation. We also examined
centro-nucleation in the mdx/SCID host muscles and in
muscles transplanted with PP2 or PP6 cells. In all cases, there
were 55%–60% fibers with central nucleation and no signif-
icant difference among the groups (Fig. 6C). We further
confirmed the donor cells’ participation in skeletal muscle
FIG. 1. Schematic isolation of human
muscle cell populations. The human
muscle biopsy is first enzymatically di-
gested, and then, the cells are preplated
on noncoated flasks. After separation of
single-cell isolates by adherence rates, two
main populations are acquired: PP2, fast
adhering cells and PP6, slow adhering
cells. Scale bars represent 100 mm. PP2,
preplate 2; PP6, preplate 6. Color images
available online at www.liebertonline
.com/tea
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regeneration by utilizing a human-specific dystrophin anti-
body and latex fluorescent beads, which co-localized with
the site of cell delivery. Comparisons of serial sections
showed that the polyclonal antibody resulted in more intense
staining (Fig. 6D) than the human specific DYS3 antibody
(Fig. 6E). Finally, we confirm donor-host fusion by detection
of host Y-chromosomes present in human dystrophin posi-
tive fibers (Fig. 6F), which shows that female donor cells fuse
with host fibers to restore dystrophin. The overall level of
dystrophin restoration by the human populations is lower
than our previous reports with mouse myoblasts and
MDSCs,21,53 and this may be that the preplate methods to
isolate potent muscle cells do not exactly translate in human
muscle tissue. In addition, the reduced dystrophin level after
FIG. 2. In vitro comparison of PP2 and PP6 muscle-derived populations. (A) Flow cytometric histograms for PP2 and PP6
populations; cells are negative for CD34, CD45, and CD144; highly positive for CD44, CD73, CD90, and CD105; and exhibit
variable expression of CD56 and CD146. (B) Flow cytometry dot plots of expression of CD146 and CD56 in slowly adhering
populations. The low level of CD146 is visible on the dot plot (CD144 is also shown here), whereas 2 distinct populations
of CD56 [+ ] and CD56 [ - ] cells are visible on the plot (separate plot with CD34 expression). (C) For both PP6 and PP2
populations, there is a significant positive correlation between the level of expression of CD146 and the myogenic marker
CD56. (D) Immunocytochemistry for desmin expression (red), with Hoechst-labeled nuclei (blue). (E) Mean in vitro
expression of CD56 (flow), CD146 (FACS), and desmin (immunocytochemistry) for PP2 and PP6 populations. Color images
available online at www.liebertonline.com/tea
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transplantation is likely attributable in part to limitations
associated with xenotransplantation. Human cells may be
challenged to survive albeit an SCID mouse, and are likely
less able to fuse with mouse myofibers, or there may be poor
dystrophin integration into the plasma membrane of hybrid
myofibers. Nevertheless, we detect significant differences
due to human cell transplantation as compared with no
transplantation or sham transplantation.
Although numerous studies describe the msMDSCs as a
potential candidate for cell therapy for skeletal muscle for
FIG. 3. (A–C) Growth characteristics of PP2 and PP6 described by (A) population doubling time (PDT), (B) division time
(DT), and (C) mitotic fraction. There were no significant differences in the growth rates between the different fractions;
however, the PP6 population had a slight trend toward slower PDT (35 h) as compared with PP2 populations (30 h). (D–F)
In vitro morphology and migration analysis. PP2 and PP6 cells described by mean cell area or spreading, circularity, and
centroid velocity. PP2 cells were significantly larger than PP2 cells, but showed no difference in cell shape or cell roundness.
We also found that PP2 were significantly less migratory than PP6 (as measured by cell velocity).
FIG. 4. In vitro myogenic characterization. (A)RT-PCRof 3 populations of PP2 cells (Lanes 1, 2, and 3), 3 populations of PP6 cells
(Lanes 4, 5, and 6), negative control—no cDNA (lane 7), and positive control—human total muscle (lane 8) for myogenic lineage
specificmarkers. (B,C)Fluorescent images of in vitromyotubes fromPP2 andPP6populations, respectively,myosin heavy chain in
red, nuclei in blue. (D) Quantification of myogenic activity of PP2 and PP6 under myogenic conditions. We detect no significant
difference in the percent of myosin positive or fused nuclei between the two populations. Scale bar represents 100mm. RT-PCR,
reverse transcription polymerase chain reaction. Color images available online at www.liebertonline.com/tea
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DMD; to date, there have been no studies to examine the
translation of this cell type to hMDSCs for skeletal muscle
repair. Here, we used the methods developed in murine
studies, to determine whether similar function cell types
could be isolated from human skeletal muscle. Translating
promising mouse studies to humans is necessary; however,
it comes with the probability that many aspects will not
readily translate. Here, we report both similarities and
differences in the mouse and human preplated muscle-
derived cells.
The preplate method was used to obtain distinct muscle cell
populations based on the different rates of cell adhesion. In
previous mouse studies, these different populations were
termed ‘‘preplates’’ and described as PP1, PP2, PP3.PP6,
where PP1 showed fast adherence, and PP6 showed the
slowest adherence.21 In this study, we compared human PP2
and PP6 cells, as mouse PP2 had been previously described as
more committed myoblasts, and PP6 cells had been described
as more stem cell-like. Similar to mouse preplate cells, we
found greater levels of myogenic markers desmin and CD56
within the myoblast-like PP2 fraction than in the human PP6
fraction. The preplate fractions were nonhomogeneous for
these markers in both our human studies here and the mouse
studies.21,25 We also describe for the first time that the human
PP6 cells express several mesenchymal stem cell markers
including CD90, CD105, CD73, and CD44. In vitro, both
fractions were able to differentiate to the myogenic lineage.
The most striking difference between the mouse myoblasts
and msMDSCs was performance in cell transplantation
studies using the mdx mice of muscular dystrophy. In this
study, we also found a significant difference in the partici-
pation of human myoblasts/PP2 as compared with human
PP6 cells—the slowly adhering PP6 cells showed a higher
level of participation in skeletal muscle repair as compared
with the human PP2 myoblasts. We found that the majority
of transplanted donor cells fused with host myofibers to give
rise to dystrophin-positive myofibers. The low level of de novo
myofiber formation, as compared with msMDSC studies, is
likely due to the xenotransplantation. This finding supports
the notion that human PP6 fraction is the human equivalent
of the msMDSC-like fraction and may, therefore, provide a
better candidate for cell therapies as compared with more
committed myoblasts.
Two aspects of the modified preplate method that remain
unresolved in mouse cell studies are (1) how does the
modified preplate method purify for MDSCs? and (2) what is
the relationship between satellite cells (in situ)/myoblasts
(in vitro) and MDSCs? Since this study demonstrates the use
of the preplate method in human tissue, it will be interesting
to investigate these questions by using human myoblasts
and hMDSCs. In the former case, it remains unknown as to
whether the preplate method isolates myoblasts and MDSC
populations that initially differ in their cell surface expres-
sion of adhesion molecules. It may also be the case that the
slowly adhering cells upregulate adhesion molecules during
the isolation process, and the adhesion characteristics are
secondary to other intrinsic differences between the cells. In
this study, both human PP2 and the human PP6 cells ex-
pressed similar levels of adhesion molecules as examined by
flow cytometry postisolation. We speculate that the preplate
method may also separate cells based on different levels of
the cells’ tolerance to anoikis,54 or anchorage-independent
induced apoptosis. There are several possibilities for which
characteristics lead to the cells’ separation during the isola-
tion method; however, the majority of msMDSC studies to
date have focused on regenerative characteristics of these
cells. A more basic understanding of hMDSC-like cells may
improve strategies for their efficient isolation and use in
transplantation studies, particularly as the preplate method
has been used to obtain human myoblasts;39,55 however,
these cells have shown only a limited regeneration capacity
in human clinical trials.12,56
FIG. 5. In vivo cell participation in muscle regeneration. (A, B) Hematoxylin and eosin stain of transplantation site for PP2
and PP6 populations. Serial section of polyclonal dystrophin antibody (C, D); fluorescent images demonstrate dystrophin
positive fibers at 2 weeks post transplantation with PP2 and PP6. (E) Quantification of the level of skeletal muscle regeneration
is measured as the regeneration index—number of dystrophin positive fibers per 105 transplanted donor cells per muscle
section. We observe significantly more dystrophin-positive myofibers after PP6 transplantation as compared with PP2 and
sham transplantation. *For PBS and no-injection muscles, no cells were injected; therefore, the y-axis represents only the
number of dystrophin-positive fibers. Scale bar represents 100mm. Color images available online at www.liebertonline.com/tea
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Although much research has focused on improving myo-
blast therapy for the treatment of skeletal muscle disease and
injury,57–59 the use of less committed MDSCs may be an al-
ternative approach. In this regard, a better understanding of
the mechanism of myoblast and MDSC separation by pre-
plating will help discern the relationship between these two
distinct populations. MDSCs may have a separate origin from
satellite cells, as MDSC (like side population cells) appear to
be present in Pax 7 knockout mice that are mainly devoid of
satellite cells,20 though Pax 7 alone has been questioned as a
reliable satellite cell marker. Although it has yet to be defini-
tively shown, it has also been hypothesized that MDSCs, and
mesenchymal stem cells, may originate from blood vessels, as
a subset of msMDSCs express endothelial markers.7 However,
we report here that the PP6 population as a whole expresses
low levels of CD146 and CD144.
The mechanism of the preplate method and the relation-
ship of myoblasts and preplate fractions are now questions
FIG. 6. Human cells’ contri-
bution to muscle regeneration
and fusion with host fibers.
(A) Histograms of diameters
of dystrophin-positive fibers
after transplantation of PP2 or
PP6, and in muscles with no
injection or transplantation.
Bins represent fiber sizes 0–
10mm, 10.1–15mm, 15.1–20mm
etc. (B) Histograms of cross-
sectional areas of dystrophin-
positive fibers after trans-
plantation of PP2 or PP6, and
in muscles with no injection or
transplantation. Bins repre-
sent fiber sizes 0–200 mm2,
200.1–400mm2, 400.1–600mm2
etc. (C) Mean fiber diameter
and (D) Mean fiber area of
dystrophin-positive fibers are
similar to host dystrophin-
negative fibers. (E) Cen-
tronucleation in dystrophin-
positive fibers is similar to
that of the host mdx/SCID
fibers. (F) and human-specific
dystrophin antibody (G) show
colocalization of the human
specific antibody with the
microsphere beads used to
identify injection site. (H) In
sex-crossed transplantations,
we also detect dystrophin-
positive fibers with host male
nuclei with Y-chromosome
labeling which shows that
some donor cells are fusing
with host fibers. Scale bar
represents 100 mm. Color
images available online at
www.liebertonline.com/tea
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that could be examined in human preplate-derived popula-
tions. Findings from early human myoblast transplantation
trials illustrate the often large disparity in results when
moving from non-human animals to human clinical trials.
Although the findings here in a DMD SCID mouse implicate
the potential development of new therapeutic cells, much
work yet remains to better characterize human muscle-
derived cells and the dynamic relationship between myo-
blasts and MDSCs populations.
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